Sandbox Reserved 15: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
Student (talk | contribs)
students
33,923 edits
No edit summary
Eric Martz (talk | contribs)
ConfirmAccount, Editor, Print3D, Tester, Bureaucrats, journal, Administrators
30,128 edits
No edit summary
 
(17 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<!-- DO NOT DELETE THE TEMPLATE LINE -->
{{Template:Sandbox Reserved Eric Martz}}
<!-- INSERT YOUR SCENES AND TEXT BELOW THIS LINE -->


== Exploring the Structure ==
<Structure load='2weu' size='350' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />
 
*<scene name='42/421645/Test_2014/1'>TextToBeDisplayed</scene>
 
Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry 2hu4). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry 3cl0). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.
Retrieved from "https://proteopedia.org/Sandbox_Reserved_15"